Remove Clinical Trials Remove Education Remove Medicine Remove Programs
article thumbnail

Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies

Cannabis Law Report

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry.

article thumbnail

Knowde Group Inc.™ Enters Into a Strategic Partnership with LMC Manna Research to Drive Quality and Collaboration in the Conduct of Cannabis and Psychedelic Clinical Trials.

Cannabis Law Report

There is an urgent need for objective, scientifically sound and robust clinical trials to support medicinal cannabis and psychedelics (psilocybin, MDMA, LSD, Ketamine). Collectively, between the two organizations we offer a full-service package from protocol development to timely and successful clinical trial execution.”.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Ohio State University: New academic center focuses on psychedelic drug research and education

Cannabis Law Report

The Center for Psychedelic Drug Research and Education (CPDRE) was approved by the Ohio State College of Social Work faculty in January, and its director, Assistant Professor of Social Work Alan Davis , officially took the helm in March. Initial goals of the center are focused on research and educational initiatives. Jason Slot.

article thumbnail

European Regulatory Lead MAPS PBC Santa Cruz, CA

Cannabis Law Report

MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics. The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times.

article thumbnail

These Patient Advocacy Groups Are Working Together to Expand the Scope of Cannabis Research

Veriheal

But one area of cannabis medicine is still lagging behind—research. In turn, cannabis advocates have struggled to properly educate the public with the limited amount of scientific evidence available. states pass relevant legislation and educating doctors about the power of cannabis medicine.

article thumbnail

Press Release: Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2

Cannabis Law Report

The Company believes it has produced a sufficient supply of cGMP DMT to complete its planned Phase 1 and Phase 2 clinical trials. as medical consultants to the Company’s DMT stroke clinical research program. in the latter part of 2022, after the Phase 1 trial has been completed. Dr. Anthony Rudd.

article thumbnail

Position: European Regulatory Lead – Remote MAPS PBC California Remote

Cannabis Law Report

MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. We are committed to continuing to lead the field of psychedelic medicine with integrity and ethics at the core. Why work for MAPS Public Benefit Corporation (MAPS PBC)?